GlassScriptPhysician profile
Regina Massaro
NPI 1235117664
$5,518.67
in general payments reported to CMS, 2019-2025
21 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,444 · 2022: $1,296 · 2023: $1,067 · 2024: $1,096 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,494.46 | 2021-2024 | Xarelto |
| Abbott Laboratories | $653.09 | 2021-2025 | Aveir, Cardiomems, Jot Dx |
| Merck Sharp & Dohme LLC | $397.56 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $389.80 | 2021-2023 | Watchman Flx, Watchman Access System |
| Novo Nordisk INC | $372.79 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $349.22 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $324.57 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $297.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $269.39 | 2021-2025 | Farxiga |
| Atricure, INC. | $266.59 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.20 | 2024 | |
| Edwards Lifesciences Corporation | $112.81 | 2023-2025 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $112.12 | 2023-2025 | |
| Urovant Sciences INC | $99.67 | 2022 | |
| Dexcom, INC. | $62.24 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $62.10 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.14 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $35.97 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.26 | 2023 | Jardiance |
| Bridgebio Pharma, INC. | $17.04 | 2025 | Attruby |
| Heartflow, INC. | $15.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Massaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.